Atopic Dermatitis Across the Lifespan: Understanding, Measuring and Minimizing Cumulative Life Course Impairment
DOI:
https://doi.org/10.2340/actadv.v106.adv-2025-0066Keywords:
atopic dermatitis, chronic disease, eczema, patient-reported outcomes, quality of life, symptom burdenAbstract
Atopic dermatitis (AD) presents a multidimensional burden, often beginning in infancy and accumulating over time. Beyond itch and pain, AD is associated with significant losses of health-related quality of life resulting from sleep disturbance, stigmatization, other atopic diseases and nonatopic comorbidities, among others. These associated conditions affect patients' physical and mental health, development, social interaction and productivity, resulting in what has been termed cumulative life course impairment (CLCI). To alter the trajectory of AD and improve patient outcomes, it is important to identify people at risk of CLCI, measure it in clinical practice and intervene with appropriate treatment. Although a digital, structured questionnaire for adults exists, a separate instrument to assess CLCI in children and adolescents would benefit our understanding of these issues in a patient population in need. This paper discusses the need for such a questionnaire, with the goal of increasing awareness of the lifelong impact of AD among healthcare professionals, caregivers and patients, potentially improving shared decision-making and facilitating conversations about treatment.
Downloads
References
Darnton-Hill I, Nishida C, James WPT. A life course approach to diet, nutrition and the prevention of chronic diseases. Public Health Nutr 2004; 7: 101–121. DOI: https://doi.org/10.1079/PHN2003584
Hanson HA, Leiser CL, Bandoli G, Pollock BH, Karagas MR, Armstrong D, et al. Charting the life course: emerging opportunities to advance scientific approaches using life course research. J Clin Transl Sci 2020; 5: e9. DOI: https://doi.org/10.1017/cts.2020.492
Kimball AB, Gieler U, Linder D, Sampogna F, Warren RB, Augustin M. Psoriasis: is the impairment to a patient’s life cumulative? J Eur Acad Dermatol Venereol 2010; 24: 989–1004. DOI: https://doi.org/10.1111/j.1468-3083.2010.03705.x
Linder MD, Piaserico S, Augustin M, Fortina AB, Cohen AD, Gieler U, et al. Psoriasis - the life course approach. Acta Derm Venereol 2016; 96: 102–108.
Doroudian Tehrani M, Gibson RS, Snyder CL, Porter ML, Kimball AB. Cumulative life course impairment: evidence for hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2025; 39: 1395–1409. DOI: https://doi.org/10.1111/jdv.20607
von Stülpnagel CC, Augustin M, Düpmann L, da Silva N, Sommer R. Mapping risk factors for cumulative life course impairment in patients with chronic skin diseases – a systematic review. J Eur Acad Dermatol Venereol 2021; 35: 2166–2184. DOI: https://doi.org/10.1111/jdv.17348
Missmer SA, Tu FF, Agarwal SK, Chapron C, Soliman AM, Chiuve S, et al. Impact of endometriosis on life-course potential: a narrative review. Int J Gen Med 2021; 14: 9–25. DOI: https://doi.org/10.2147/IJGM.S261139
Silverberg NB, Durán-McKinster C. Special considerations for therapy of pediatric atopic dermatitis. Dermatol Clin 2017; 35: 351–363. DOI: https://doi.org/10.1016/j.det.2017.02.008
Brenninkmeijer EEA, Legierse CM, Sillevis Smitt JH, Last BF, Grootenhuis MA, Bos JD. The course of life of patients with childhood atopic dermatitis. Pediatr Dermatol 2009; 26: 14–22. DOI: https://doi.org/10.1111/j.1525-1470.2008.00745.x
Arancio LMH, D’Amico D, Dastoli S, Fiorella CS, Manfredini M, Moretta G, et al. Early intervention and cumulative life course impairment in psoriasis: a review. Clin Exp Dermatol 2024; 49: 1525–1531. DOI: https://doi.org/10.1093/ced/llae282
Felix PAO, Sampaio AL, Silva BL, Viana ALP. Early intervention in psoriasis: Where do we go from here? Front Med 2022; 9: 1027347. DOI: https://doi.org/10.3389/fmed.2022.1027347
Romiti R, Magalhães RF, Duarte GV. Cumulative life course impairment in patients with dermatological diseases, with a focus on psoriasis. An Bras Dermatol 2024; 99: 269–276. DOI: https://doi.org/10.1016/j.abd.2023.08.006
Fasseeh AN, Elezbawy B, Korra N, Tannira M, Dalle H, Aderian S, et al. Burden of atopic dermatitis in adults and adolescents: a systematic literature review. Dermatol Ther (Heidelb) 2022; 12: 2653–2668. DOI: https://doi.org/10.1007/s13555-022-00819-6
Hon KL, Tsang YCK, Poon TCW, Pong NH, Kwan M, Lau S, et al. Predicting eczema severity beyond childhood. World J Pediatr 2016; 12: 44–48. DOI: https://doi.org/10.1007/s12519-015-0064-9
Achten R, Van der Rijst L, Piena M, Lamers H, De Beer F, De Bruin-Weller M, et al. Economic and humanistic burden in paediatric patients with atopic dermatitis. Acta Derm Venereol 2023; 103: adv00881. DOI: https://doi.org/10.2340/actadv.v103.4842
Stingeni L, Belloni Fortina A, Baiardini I, Hansel K, Moretti D, Cipriani F. Atopic dermatitis and patient perspectives: insights of bullying at school and career discrimination at work. J Asthma Allergy 2021; 14: 919–928. DOI: https://doi.org/10.2147/JAA.S317009
Weidinger S, Simpson EL, Silverberg JI, Barbarot S, Eckert L, Mina-Osorio P, et al. Burden of atopic dermatitis in paediatric patients: an international cross-sectional study. Br J Dermatol 2024; 190: 846–857. DOI: https://doi.org/10.1093/bjd/ljad449
Augustin M, Misery L, von Kobyletzski L, Mealing S, Redding M, Chuang CC, et al. Systematic literature review assessing the overall costs and societal impacts of moderate‐to‐severe atopic dermatitis in Europe. J Eur Acad Dermatol Venereol 2022; 36: 2316–2324. DOI: https://doi.org/10.1111/jdv.18481
Chung J, Simpson EL. The socioeconomics of atopic dermatitis. Ann Allergy Asthma Immunol 2019; 122: 360–366. DOI: https://doi.org/10.1016/j.anai.2018.12.017
Ramirez FD, Chen S, Langan SM, Prather AA, McCulloch CE, Kidd SA, et al. Association of atopic dermatitis with sleep quality in children. JAMA Pediatr 2019; 173: e190025. DOI: https://doi.org/10.1001/jamapediatrics.2019.0025
Chang YS, Chiang BL. Sleep disorders and atopic dermatitis: A 2-way street? J Allergy Clin Immunol 2018; 142: 1033–1040. DOI: https://doi.org/10.1016/j.jaci.2018.08.005
Cameron S, Donnelly A, Broderick C, Arichi T, Bartsch U, Dazzan P, et al. Mind and skin: exploring the links between inflammation, sleep disturbance and neurocognitive function in patients with atopic dermatitis. Allergy 2024; 79: 26–36. DOI: https://doi.org/10.1111/all.15818
Silverberg JI, Paller AS. Association between eczema and stature in 9 US population-based studies. JAMA Dermatol 2015; 151: 401–409. DOI: https://doi.org/10.1001/jamadermatol.2014.3432
Wu D, Wu XD, Zhou X, Huang W, Luo C, Liu Y. Bone mineral density, osteopenia, osteoporosis, and fracture risk in patients with atopic dermatitis: a systematic review and meta- analysis. Ann Transl Med 2021; 9: 40. DOI: https://doi.org/10.21037/atm-20-4708
Romanos M, Gerlach M, Warnke A, Schmitt J. Association of attention-deficit/hyperactivity disorder and atopic eczema modified by sleep disturbance in a large population-based sample. J Epidemiol Community Health 2010; 64: 269–273. DOI: https://doi.org/10.1136/jech.2009.093534
Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol 2013; 131: 428–433. DOI: https://doi.org/10.1016/j.jaci.2012.10.041
Schans J van der, Çiçek R, de Vries TW, Hak E, Hoekstra PJ. Association of atopic diseases and attention-deficit/hyperactivity disorder: a systematic review and meta-analyses. Neurosci Biobehav Rev 2017; 74: 139–148. DOI: https://doi.org/10.1016/j.neubiorev.2017.01.011
Ma EZ, Chang HR, Radtke S, Wan J. Symptoms of cognitive impairment among children with atopic dermatitis. JAMA Dermatol 2024; 160: 447–452. DOI: https://doi.org/10.1001/jamadermatol.2024.0015
Huang AH, Roh YS, Sutaria N, Choi J, Williams KA, Canner JK, et al. Real-world comorbidities of atopic dermatitis in the pediatric ambulatory population in the United States. J Am Acad Dermatol 2021; 85: 893–900. DOI: https://doi.org/10.1016/j.jaad.2021.03.016
Thyssen JP, Halling AS, Schmid-Grendelmeier P, Guttman-Yassky E, Silverberg JI. Comorbidities of atopic dermatitis-what does the evidence say? J Allergy Clin Immunol 2023; 151: 1155–1162. DOI: https://doi.org/10.1016/j.jaci.2022.12.002
Bantz SK, Zhu Z, Zheng T. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. J Clin Cell Immunol 2014; 5: 202.
Choi UE, Deng J, Parthasarathy V, Liao V, D’Amiano A, Taylor M, et al. Risk factors and temporal associations of progression of the atopic march in children with early-onset atopic dermatitis. J Am Acad Dermatol 2025; 92: 732–740. DOI: https://doi.org/10.1016/j.jaad.2024.10.107
Silverberg JI, Simpson EL. Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization. Pediatr Allergy Immunol 2013; 24: 476–486. DOI: https://doi.org/10.1111/pai.12095
Dierick BJH, van der Molen T, Flokstra-de Blok BMJ, Muraro A, Postma MJ, Kocks JWH, et al. Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy. Expert Rev Pharmacoecon Outcomes Res 2020; 20: 437–453. DOI: https://doi.org/10.1080/14737167.2020.1819793
Haanpää L, Af Ursin P, Nermes M, Kaljonen A, Isolauri E. Association of allergic diseases with children’s life satisfaction: population-based study in Finland. BMJ Open 2018; 8: e019281. DOI: https://doi.org/10.1136/bmjopen-2017-019281
Valero-Moreno S, Torres-Llanos R, Pérez-Marín M. Impact of childhood food allergy on quality of life: a systematic review. Appl Sci 2024; 14: 10989. DOI: https://doi.org/10.3390/app142310989
Nanda MK, LeMasters GK, Levin L, Rothenberg ME, Assa’ad AH, Newman N, et al. Allergic diseases and internalizing behaviors in early childhood. Pediatrics 2016; 137: e20151922. DOI: https://doi.org/10.1542/peds.2015-1922
Rønnstad ATM, Halling-Overgaard AS, Hamann CR, Skov L, Egeberg A, Thyssen JP. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis. J Am Acad Dermatol 2018; 79: 448–456. DOI: https://doi.org/10.1016/j.jaad.2018.03.017
Kern C, Wan J, LeWinn KZ, Ramirez FD, Lee Y, McCulloch CE, et al. Association of atopic dermatitis and mental health outcomes across childhood: a longitudinal cohort study. JAMA Dermatol 2021; 157: 1200–1208. DOI: https://doi.org/10.1001/jamadermatol.2021.2657
Johnson JK, Loiselle A, Chatrath S, Smith Begolka W. Patient and caregiver perspectives on the relationship between atopic dermatitis symptoms and mental health. Dermatitis 2024; 35: 386–391. DOI: https://doi.org/10.1089/derm.2023.0365
Hou A, Silverberg JI. Predictors and age-dependent pattern of psychologic problems in childhood atopic dermatitis. Pediatr Dermatol 2021; 38: 606–612. DOI: https://doi.org/10.1111/pde.14588
Neri I, Galli E, Baiardini I, Picozza M, Rossi AB, Matruglio P, et al. Implications of atopic dermatitis on the quality of life of 6–11-year-old children and caregivers (PEDI-BURDEN). J Asthma Allergy 2023; 16: 383–396. DOI: https://doi.org/10.2147/JAA.S404350
Hua T, Silverberg JI. Atopic dermatitis in US adults: epidemiology, association with marital status, and atopy. Ann Allergy Asthma Immunol 2018; 121: 622–624. DOI: https://doi.org/10.1016/j.anai.2018.07.019
von Kobyletzki L, Henrohn D, Ballardini N, Neary MP, Ortsäter G, Rieem Dun A, et al. Comorbidities in childhood atopic dermatitis: a population‐based study. J Eur Acad Dermatol Venereol 2024; 38: 354–364. DOI: https://doi.org/10.1111/jdv.19569
Wang V, Boguniewicz J, Boguniewicz M, Ong PY. The infectious complications of atopic dermatitis. Ann Allergy Asthma Immunol 2021; 126: 3–12. DOI: https://doi.org/10.1016/j.anai.2020.08.002
Silverberg JI, Garg NK, Paller AS, Fishbein AB, Zee PC. Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. J Invest Dermatol 2015; 135: 56–66. DOI: https://doi.org/10.1038/jid.2014.325
Girolomoni G, Luger T, Nosbaum A, Gruben D, Romero W, Llamado LJ, et al. The economic and psychosocial comorbidity burden among adults with moderate-to-severe atopic dermatitis in Europe: analysis of a cross-sectional survey. Dermatol Ther 2021; 11: 117–130. DOI: https://doi.org/10.1007/s13555-020-00459-8
Mohr N, Augustin M, Zeervi L, Bieber T, Werfel T, Wollenberg A, et al. Determinants of costs and benefits in atopic dermatitis routine care in Germany. J Eur Acad Dermatol Venereol 2022; 36: 1450–1455. DOI: https://doi.org/10.1111/jdv.18169
Wan J, Fuxench ZCC, Wang S, Syed MN, Shin DB, Abuabara K, et al. Incidence of cardiovascular disease and venous thromboembolism in patients with atopic dermatitis. J Allergy Clin Immunol Pract 2023; 11: 3123–3132. DOI: https://doi.org/10.1016/j.jaip.2023.08.007
Lee SW, Kim H, Byun Y, Baek YS, Choi CU, Kim JH, et al. Incidence of cardiovascular disease after atopic dermatitis development: a nationwide, population-based study. Allergy Asthma Immunol Res 2023; 15: 231–245. DOI: https://doi.org/10.4168/aair.2023.15.2.231
Augustin M, Radtke MA, Glaeske G, Reich K, Christophers E, Schaefer I, et al. Epidemiology and comorbidity in children with psoriasis and atopic eczema. Dermatology 2015; 231: 35–40. DOI: https://doi.org/10.1159/000381913
Ascott A, Mansfield KE, Schonmann Y, Mulick A, Abuabara K, Roberts A, et al. Atopic eczema and obesity: a population-based study. Br J Dermatol 2021; 184: 871–879. DOI: https://doi.org/10.1111/bjd.19597
Augustin M, Langenbruch A, Blome C, Gutknecht M, Werfel T, Ständer S, et al. Characterizing treatment‐related patient needs in atopic eczema: insights for personalized goal orientation. Acad Dermatol Venereol 2020; 34: 142–152. DOI: https://doi.org/10.1111/jdv.15919
Irvine AD, Mina-Osorio P. Disease trajectories in childhood atopic dermatitis: an update and practitioner’s guide. Br J Dermatol 2019; 181: 895–906. DOI: https://doi.org/10.1111/bjd.17766
Jacobson ME, Seshadri RS, Morimoto R, Grinich E, Haag C, Nguyen K, et al. Early intervention and disease modification in atopic dermatitis-the current state of the field and barriers to progress. J Eur Acad Dermatol Venereol 2024; 38: 665–672. DOI: https://doi.org/10.1111/jdv.19699
Ranzinger D, Eyerich K. Disease modification in psoriasis: future prospects for long-term remission. Am J Clin Dermatol 2025; 26: 477–486. DOI: https://doi.org/10.1007/s40257-025-00949-5
Bieber T. Disease modification in inflammatory skin disorders: opportunities and challenges. Nat Rev Drug Discov 2023; 22: 662–680. DOI: https://doi.org/10.1038/s41573-023-00735-0
Bacci ED, Correll JR, Pierce EJ, Atwater AR, Dawson Z, Begolka WS, et al. Burden of adult atopic dermatitis and unmet needs with existing therapies. J Dermatolog Treat 2023; 34: 2202288. DOI: https://doi.org/10.1080/09546634.2023.2202288
Paller AS, Guttman-Yassky E, Schuttelaar MLA, Irvine AD, Baselga E, Kataoka Y, et al. Disease characteristics, comorbidities, treatment patterns and quality of life impact in children <12 years old with atopic dermatitis: interim results from the PEDISTAD Real-World Registry. J Am Acad Dermatol 2022; 87: 1104–1108. DOI: https://doi.org/10.1016/j.jaad.2022.01.018
Eyerich K, Gooderham MJ, Silvestre JF, Shumack SP, Mendes-Bastos P, Aoki V, et al. Real-world clinical, psychosocial and economic burden of atopic dermatitis: results from a multicountry study. J Eur Acad Dermatol Venereol 2024; 38:340–353. DOI: https://doi.org/10.1111/jdv.19500
Kleyn CE, Barbarot S, Reed C, Losi S, von Arx LB, Robert C, et al. Burden of moderate to severe atopic dermatitis in adults from France, Italy, and the UK: patient-reported outcomes and treatment patterns. Dermatol Ther 2022; 12: 1947–1965. DOI: https://doi.org/10.1007/s13555-022-00777-z
Calzavara-Pinton P, Čelakovská J, Lapeere H, Holzer G, Al-Ahmad M, Chu CY, et al. Baseline demographics, comorbidities, treatment patterns and burden of atopic dermatitis in adults and adolescents from the GLOBOSTAD long-term observational study. Adv Ther 2023; 40: 5366–5382. DOI: https://doi.org/10.1007/s12325-023-02644-5
Lin TL, Fan YH, Fan KS, Juan CK, Chen YJ, Wu CY. Reduced atopic march risk in pediatric atopic dermatitis patients prescribed dupilumab versus conventional immunomodulatory therapy: a population-based cohort study. J Am Acad Dermatol 2024; 91: 466–473. DOI: https://doi.org/10.1016/j.jaad.2024.05.029
Strober B, Mallya UG, Yang M, Ganguli S, Gadkari A, Wang J, et al. Treatment outcomes associated with dupilumab use in patients with atopic dermatitis: 1-year results from the RELIEVE-AD study. JAMA Dermatol 2022; 158: 142–150 DOI: https://doi.org/10.1001/jamadermatol.2021.4778
Braren-von Stülpnagel CC, Augustin M, Westphal L, Sommer R. Development of measurement tools to assess cumulative life course impairment in patients with chronic skin diseases. J Eur Acad Dermatol Venereol 2023; 37: 1626–1633. DOI: https://doi.org/10.1111/jdv.18977
Ho MJ, Sultana R, Choo K, Lee HY. Cumulative life course impairment in moderate-to-severe atopic dermatitis: a cross-sectional study in Singapore. Dermatology 2025; 241: 425–436. DOI: https://doi.org/10.1159/000548368
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–216. DOI: https://doi.org/10.1111/j.1365-2230.1994.tb01167.x
Hanifin JM, Baghoomian W, Grinich E, Leshem YA, Jacobson M, Simpson EL. The Eczema Area and Severity Index—a practical guide. Dermatitis 2022; 33: 187–192. DOI: https://doi.org/10.1097/DER.0000000000000895
Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol 2004; 140: 1513–1519. DOI: https://doi.org/10.1001/archderm.140.12.1513
Augustin M. Cumulative life course impairment: identifying patients at risk. Curr Probl Dermatol 2013; 44: 74–81. DOI: https://doi.org/10.1159/000350555
Heratizadeh A, Mempel M, von Kiedrowski R, Hagl S, Mosch T, Fritz B, et al. Checklist identification of candidates for systemic therapy in adult patients with atopic dermatitis in Germany: a multicentre study. J Eur Acad Dermatol Venereol 2024; 38: 157–166. DOI: https://doi.org/10.1111/jdv.19465
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
